Stephen J. Hoffman
Directeur/Membre du Conseil chez RESEARCH ALLIANCE CORP. II
Fortune : 2 708 $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Peter Kolchinsky | M | 47 | 11 ans | |
Vivienne Margaret Jackson | F | - |
BYOMass, Inc.
BYOMass, Inc. Miscellaneous Commercial ServicesCommercial Services BYOMass, Inc. provides investment holding services. The company is headquartered in Sudbury, MA. | - |
Vincent Angotti | M | 56 | 7 ans | |
Traci Carman | F | - |
Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA. | 9 ans |
James B. Weissman | M | 62 |
Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA. | 11 ans |
Matthew Hammond | M | 35 | 4 ans | |
Garry Llewellyn Redlich | M | - |
Implicit Bioscience Ltd.
Implicit Bioscience Ltd. BiotechnologyHealth Technology Implicit Bioscience Ltd. operates as a clinical-stage immunotherapy drug development company. It develops drugs that modulate the host immune response to disease. The firm develops small molecule dipeptide oglufanide disodium for community and hospital-acquired infections including those caused by bio-threat agents. The company was founded by Garry Llewellyn Redlich, Peter Ronald Andrews and Ian Hector Frazer and is headquartered in Woolloongabba, Australia. | - |
Pamela Palmer | M | 61 | 19 ans | |
Ken Bate | M | 73 | 10 ans | |
Gregory F Wesner | M | - |
Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA. | 9 ans |
Ian Hector Frazer | M | - |
Implicit Bioscience Ltd.
Implicit Bioscience Ltd. BiotechnologyHealth Technology Implicit Bioscience Ltd. operates as a clinical-stage immunotherapy drug development company. It develops drugs that modulate the host immune response to disease. The firm develops small molecule dipeptide oglufanide disodium for community and hospital-acquired infections including those caused by bio-threat agents. The company was founded by Garry Llewellyn Redlich, Peter Ronald Andrews and Ian Hector Frazer and is headquartered in Woolloongabba, Australia. | - |
Marion Koster | F | - |
Implicit Bioscience Ltd.
Implicit Bioscience Ltd. BiotechnologyHealth Technology Implicit Bioscience Ltd. operates as a clinical-stage immunotherapy drug development company. It develops drugs that modulate the host immune response to disease. The firm develops small molecule dipeptide oglufanide disodium for community and hospital-acquired infections including those caused by bio-threat agents. The company was founded by Garry Llewellyn Redlich, Peter Ronald Andrews and Ian Hector Frazer and is headquartered in Woolloongabba, Australia. | - |
Mark Theeuwes | M | - |
Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA. | 3 ans |
Raffi Asadorian | M | 54 | 7 ans | |
Christian Mueller | M | - |
Apic Bio, Inc.
Apic Bio, Inc. Packaged SoftwareTechnology Services Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA. | 7 ans |
Clive Patience | M | 60 | 4 ans | |
Orrin Devinsky | M | 67 |
Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA. | 6 ans |
Andrea Leone-Bay | M | - |
Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA. | 9 ans |
Peter Ronald Andrews | M | - |
Implicit Bioscience Ltd.
Implicit Bioscience Ltd. BiotechnologyHealth Technology Implicit Bioscience Ltd. operates as a clinical-stage immunotherapy drug development company. It develops drugs that modulate the host immune response to disease. The firm develops small molecule dipeptide oglufanide disodium for community and hospital-acquired infections including those caused by bio-threat agents. The company was founded by Garry Llewellyn Redlich, Peter Ronald Andrews and Ian Hector Frazer and is headquartered in Woolloongabba, Australia. | - |
Travis Thompson | M | - | 6 ans | |
Jeffrey R. Latts | M | 76 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 17 ans |
Thomas Leggett | M | 47 | 3 ans | |
Adrian Adams | M | 73 | 11 ans | |
Bob D. Brown | M | 59 | 16 ans | |
Mark A. Evashenk | M | - | 15 ans | |
Jill Broadfoot | F | 63 | 3 ans | |
Marina Bozilenko | F | 59 | 3 ans | |
Edward Braginsky | M | - |
TVM Capital Corp.
TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts. | 19 ans |
Jens Eckstein | M | 60 |
TVM Capital Corp.
TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts.
Palleon Pharma, Inc.
Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | - |
Mark Wan | M | 58 | 18 ans | |
Jim Broderick | M | 55 |
Palleon Pharma, Inc.
Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | - |
Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 ans |
Daniel Geffken | M | 67 |
Apic Bio, Inc.
Apic Bio, Inc. Packaged SoftwareTechnology Services Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA. | 6 ans |
Tess Cameron | F | - | 4 ans | |
Ulrich Christian Otte | M | - | 3 ans | |
Jamie Haney | F | - | 3 ans | |
Abhinav Jain | M | - | - | |
Warren Lammert | M | - |
Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA. | - |
Monika Schlesinger | F | - |
TVM Capital GmbH
TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | 19 ans |
Robert D. Ciappenelli | M | 57 | 5 ans | |
David J. Caponera | M | 67 | 5 ans | |
Thomas Haagen | M | 58 | 3 ans | |
Badri Dasu | M | 61 | 17 ans | |
Timothy Cunningham | M | 62 |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | 4 ans |
Felix von Coerper | M | - |
Apic Bio, Inc.
Apic Bio, Inc. Packaged SoftwareTechnology Services Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA. | 5 ans |
Jason Robert Dinges | M | 48 |
Apic Bio, Inc.
Apic Bio, Inc. Packaged SoftwareTechnology Services Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA. | 6 ans |
Peter Ludlum | M | 68 |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | 3 ans |
Norman Staskey | M | 54 |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | 3 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Michael Rogers | M | 64 | 2 ans | |
Regina Marek | F | 55 | 3 ans | |
Douglas Fambrough | M | 55 | 14 ans | |
Richard A. King | M | 59 | 5 ans | |
Thomas A. Schreck | M | 67 | 8 ans | |
Jonathan Michael Poole | M | 49 | 4 ans | |
Katrine Bosley | F | 56 | - | |
Lee Kalowski | M | 43 | 6 ans | |
Christoph H. Westphal | M | 56 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 6 ans |
Mark G. Edwards | M | 66 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 20 ans |
Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 ans |
Michael E. Hart | M | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 5 ans |
Kevin Bitterman | M | 47 | 11 ans | |
James Welch | M | 66 | 4 ans | |
J. Buchi | M | 69 | 3 ans | |
Jane Wright-Mitchell | F | 55 | 3 ans | |
David Sinclair | M | - |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 7 ans |
Howard Rosen | M | 66 | 16 ans | |
Cynthia Smith | F | 55 | 3 ans | |
Gregory Paul Watson | M | 68 | 12 ans | |
Nishan de Silva | M | 51 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 ans |
Ling Zeng | F | 55 | 2 ans | |
Carolyn Ng | M | 40 | 2 ans | |
Simeon George | M | 46 | 5 ans | |
Ronald Cooper | M | 61 | 5 ans | |
Kristen K. Sheppard | F | - | 1 ans | |
Howard Mayer | M | 62 | 3 ans | |
Michael Anstey | M | 43 | 3 ans | |
Dhaval Desai | M | - | 4 ans | |
Patrick M. Gray | M | 75 | 2 ans | |
Kimberley Gaumer | F | - | - | |
Adam Koppel | M | 54 | 4 ans | |
Jonathan Lieber | M | 54 |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | 3 ans |
Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 ans |
Jonathan Leff | M | 55 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 7 ans |
Paul Schimmel | M | 83 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Guy Nohra | M | 63 | 7 ans | |
David Clark | M | 56 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 ans |
Vincent J. Miles | M | 73 | 1 ans | |
Marc H. Graboyes | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 ans |
Marc Kozin | M | 62 | 2 ans | |
Cheryl L. Cohen | F | 58 | 3 ans | |
David Michael Madden | M | 61 | 10 ans | |
David Sinclair | M | 55 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
David Stout | M | 69 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 ans |
John Green | M | 43 | 6 ans | |
Brian Halak | M | 52 | 9 ans | |
Peter Elliott | M | 64 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Karen May | F | 65 | 15 ans | |
Eashwar Viswanathan Krishnan | M | 47 | - | |
Stephen Doberstein | M | 65 | 1 ans | |
Michael Higgins | M | 61 | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 90 | 90,00% |
Royaume-Uni | 5 | 5,00% |
Australie | 4 | 4,00% |
Allemagne | 1 | 1,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Stephen J. Hoffman
- Réseau Personnel